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Abstract
Background: It has been reported that rs4446909, a single nucleotide polymorphism (SNP) in the promoter of
acetylserotonin methyltransferase (ASMT), influences the expression of the ASMT enzyme. The common G allele is
associated with lower ASMT activity, and therefore, diminishes conversion of N-acetylserotonin to melatonin. The G
allele was associated with recurrent depressive disorder in a Polish group. ASMT might also affect bipolar relapse,
given evidence that N-acetylserotonin might stimulate TRKB receptors, and TRKB may influence mood relapse in
bipolar disorder. Additionally, arylalkylamine N-acetyltransferase (AANAT) polymorphisms have been reported
associated with depression, perhaps through their influence upon N-acetylserotonin or melatonin synthesis.
Results: To replicate and further explore these ideas, rs4446909 was genotyped in four research groups, as part of
a panel of 610 SNPs surveyed by an Illumina Golden Gate assay. In 768 cases with delayed sleep phase disorder or
matched controls, rs4446909 was indeed associated with the depressive symptoms on a self-report scale (P = 0.01,
R
2 = 0.007). However, there was no significant association of rs4446909 with self-reported depression in a sleep
clinic patient group or with two groups of elderly men and women from multicenter studies, nor was the
response to lithium treatment associated with rs4446909 in bipolar patients. No associations of two AANAT SNPs
with depression were found.
Conclusions: The evidence did not support a strong influence of rs4446909 upon mood, but the partial replication
may be consistent with a modest effect. It is possible that larger or younger subject groups with improved
phenotype ascertainment might demonstrate more persuasive replication.
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Background
The psychiatric literature contains a number of inconsis-
tent studies of melatonin in affective disorders, reporting
that there is a “low melatonin syndrome” or high morn-
ing melatonin associated with depression, or that the
timing of melatonin secretion may be either advanced
or delayed [1-7]. The circadian phase of melatonin
secretion has been hypothesized to be a causal element
in affective disorders. New evidence suggests that late
melatonin elevations may suppress pars tuberalis TEF, a
photoperiodic switch which might control human
depression [8]. Such a mechanism would be consistent
with apparent comorbidity of delayed sleep phase disor-
der and depression [9]. The problems contributing to
inconsistent theories about melatonin’sr o l ei nd e p r e s -
sion include the difficulties of obtaining complete over-
night melatonin secretion profiles from onset to offset,
especially in very disturbed patients, assay difficulties,
differences between the home and hospital environ-
ments, effects of medications, and the heterogeneity of
patient samples.
Since affective disorders appear strongly related to
genetic susceptibilities [10], there is hope that modern
genetics may clarify the pathological mechanisms in
production of melatonin associated with affective disor-
ders. However, the notorious risks of false-positive and
non-generalizable reports of genetic association make
critical replication essential [11].
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morphism (SNP) in acetylserotonin methyltransferase
(ASMT) was associated with depression in a Polish
group of 181 patients with recurrent depressive disor-
ders contrasted to 149 controls [12]. Being a homozy-
gote for the less common A allele of the rs4446909 SNP
was protectively associated with a much lower risk of
recurrent depression (odds ratio = 0.1; 95% CI = 0.03-
0.58; P = 0.007), whereas the common G allele was asso-
ciated with more depression. One or two G alleles were
observed in 99% of cases and 92% of controls. An addi-
tional nearby ASMT polymorphism, rs5989681, came
close to significant association with recurrent depressive
disorders. Furthermore, ASMT RNA extracted from
whole blood was lower among depressed patients than
among controls, and was lower among those with the
GG genotype for rs4446909. Since ASMT converts N-
acetylserotonin to melatonin (Figure 1), the Polish data
were interpreted as consistent with a hypothesized low
melatonin syndrome in depression [1].
Previously, Melke and colleagues had reported that the
G alleles in these same polymorphisms, rs4446909 and
rs5989681, reduced ASMT transcription and resulted in
low melatonin among autistic children [13]. The G
alleles also lowered ASMT activity in unaffected indivi-
duals [13]. These polymorphisms evidently alter tran-
scription factor binding sites in the ASMT promoter
[14]. A microduplication in ASMT may also be common
in autism [15] though this is unclear [16].
More recently, Soria et al. reported that 3 SNPs in
AANAT, rs3760138, rs4238989, and rs8150 were
modestly associated with depression in a Spanish sam-
ple, and the global significance of contrasting haplotypes
of these SNPs was P = 6.9 × 10
-34 [17]. They could not
report replication of the associations of these three
SNPs in other studies, but a fourth SNP, rs11077820,
was significantly associated with depression both in
their study and in one subsample of an independent
study [17]. The effects of these SNPs on conversion of
serotonin to N-acetylserotonin have not been
investigated.
When ASMT activity is reduced and less melatonin is
produced, N-acetylserotonin might accumulate to higher
concentrations (Figure 1), which might explain the
observation of increased serotonin (the precursor of N-
acetylserotonin) among subjects with reduced ASMT
activity [13]. However, in animal models, N-acetylsero-
tonin has an antidepressant-like action [18]. Alterations
in the activity of AANAT might also modulate N-acetyl-
serotonin, though regulation of AANAT activity may be
largely post-transcriptional [19]. These ideas seem rele-
vant to a recent report that N-acetylserotonin activates
neurotrophic tyrosine kinase receptor, type 2 (TRKB), a
brain-derived neurotrophic factor (BDNF) receptor tran-
scribed from the NTRK2 gene. BDNF binding to TRKB
may modulate neuronal survival, neurogenesis, and
synaptic plasticity [18,20-22]. Thus, a polymorphism
reducing ASMT RNA expression and protein activity, by
increasing accumulation of N-acetylserotonin, might
potentiate actions of TRKB and BDNF. This may be
relevant to clinical interests, since colleagues from Dr.
Kelsoe’s group have shown that the rs1387923 poly-
morphism near NTRK2 is associated with the effective-
ness of lithium in preventing relapses of bipolar disorder
(many relapses are depressive episodes,) and NTRK2
alleles may be associated with suicide [19,23,24]. Theo-
retically, both ASMT and AANAT polymorphisms might
modulate responsiveness to lithium through TRKB.
With an interest in extending and replicating the
recent associations of AANAT and ASMT polymorph-
isms with depression, we examined the influence of
SNPs in these genes on depression, the circadian trait of
morningness-eveningness, and lithium-treatment
response in groups of research participants in which our
teams had already assayed certain ASMT and AANAT
SNPs.
Methods
Participants
This study utilized previous assays of DNA from five
research studies (Table 1). All data were collected with
written informed consent, approved by the review
boards of the participating institutions.
First, 768 participants in as t u d yo ft h eg e n e t i c so f
delayed sleep phase disorder (DSPD) were about half
Serotonin
TRKB
N-acetylserotonin NTRK2
Melatonin
Arylalkylamine N-acetyltransferase
(AANAT) rs11077821, rs8150, &    rs12942767
Acetylserotonin methyltransferase
(ASMT) rs4446909
rs1387923
Figure 1 The metabolic pathway converting serotonin to
melatonin involves the enzymes AANAT and ASMT (previously
known as HIOMT). Although AANAT has been believed to control
the rate-limiting step, recent studies [13] imply an effect of ASMT
upon the metabolic conversion of serotonin to melatonin. The
activity of both AANAT and ASMT might influence the
concentration of N-acetylserotonin, which influences expression of
TRKB (a BDNF receptor).
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majority of European ancestry [9]. Their ages ranged
from 22 to 82 with a median of 35 years, and 67% were
female.
Second, Scripps Clinic Viterbi Family Sleep Center
patient volunteers included 853 who underwent diag-
nostic polysomnography for sleep complaints. Their
ages ranges from 21 to 96 years (median 57), 65% were
male, and 88% were of European ancestry. At least half
of these patients had more than average sleep respira-
tory disturbance; insomnia, restless legs syndrome, and
delayed sleep phase disorders were also common. The
UCSD DSPD and Scripps participants each completed
the Quick Inventory of Depressive Symptomatology
Self-Report questionnaire (QIDS-SR) for evaluation of
current-state depression, a scale highly correlated with
the gold-standard Hamilton Depression Rating Scale
[25]. Although the QIDS-SR score is well correlated
with research diagnoses of current major depressive epi-
sodes [26] and therefore, is associated with a lifetime
diagnosis of recurrent major depressive disorder, it does
not always provide an accurate reflection of the lifetime
history of depression, since patients may have been
more depressed at prior times in their lives. Participants
also completed the BALM morningness-eveningness
scale, a simplified scale well-correlated with the Horne-
Östberg morningness-eveningness scale for measuring
circadian traits [9,27].
Third, in the Osteoporotic Fractures in Men (MrOS)
Study [28,29], 5,994 ambulatory community-living
m a l e sa tl e a s ta g e6 5y e a r sa ts t u d ye n t r yw e r e
recruited at 6 clinical centers in the U.S. (Birmingham,
A L ,M i n n e a p o l i s ,M N ,P a l oA l t o ,C A ,P i t t s b u r g h ,P A ,
Portland OR, and San Diego, CA.) This analysis
included 2540 participants self-reporting white race
who had given DNA samples, and who 3.5 years after
entry at ages ranging from 67-96 years (median 76)
participated in a MrOS Sleep ancillary study (Out-
comes of Sleep Disorders in Older Men), when they
completed the Geriatric Depression Scale (GDS) [30].
Like the QIDS-SR, the GDS is no exact measure of
lifetime depression susceptibility, but log10[1+GDS]
was used as an indicator of current depression state in
the geriatric age group.
Fourth, the Study of Osteoporotic Fractures (SOF) is a
study focusing on community-dwelling Caucasian
women over age 65 years recruited at 4 centers: The
University of Maryland (Baltimore), the University of
Minnesota, the University of Pittsburgh, and The Kaiser
Permanente Center for Health Research (Portland) [31].
From an original cohort of 9,704 elderly women, 2431
with available DNA were genotyped as part of a study
of circadian genes and sleep, of which 1,786 attended
visit 8 where the GDS was ascertained. At this point,
they were from 79-99 years of age (median 83 years.)
Included in the study were 1,731 women with genotype
data, after exclusion of those with missing values for
GDS.
Fifth, VA San Diego Health Care System participants
were patients with bipolar affective disorder receiving
lithium to prevent relapse. Patients with bipolar disorder
were interviewed using the Diagnostic Interview for
Genetic Studies (DIGS). As part of this interview, they
were queried regarding past medication trials using a
life chart method. Information from the patient, medical
records and family informants were considered by a
panel of blind clinical raters. All trials of lithium were
considered, and episode frequency on and off lithium
were compared. Greater weighting was allowed for
monotherapy trials. Response was scored as good for
50% reduction in episodes and not good for those with
less or no response. These data were also used to rate
l i t h i u mr e s p o n s eu s i n gt h eA l d as c a l e ,w h i c hs c o r e s
response on a 1-10 scale and corrects for poor informa-
tion or compliance [32]. Analyses were restricted to 80
bipolar patients of European ancestry to avoid stratifica-
tion artifacts. Their ages ranged from 21 to 67 years
(median 46), and 63% were male.
Assay Methods
The CPMC investigators, the UCSD group, and the
Scripps Clinic researchers had collaborated to develop
an assay for polymorphisms in circadian and sleep-
related genes. A custom Illumina Golden Gate assay was
developed to genotype 768 SNPs, of which 610 were
found to yield heterozygous alleles in Hardy-Weinberg
equilibrium and adequate assay quality, e.g., as judged
by 99.4% genotype calling. This assay included 12 SNPs
Table 1 Studies Included
Study Participants N % Male Median age (range) Diagnoses
Delayed sleep phase disorder Cases and Controls 768 33% 35 (22-82) DSPD or no DSPD
Sleep Clinic Scripps sleep disorders patients 853 65% 57 (21-96) Sleep apnea, DSPD, insomnia, etc.
MrOS Volunteers, multi-center 2540 100% 76 (67-96) Mixed diagnoses or none
SOF Volunteers, multi-center 1731 0% 83 (79-99) Mixed diagnoses or none
Bipolar disorder VA clinic patients 80 63% 46 (21-67) All had bipolar disorder
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SNPs that were selected for a combination of possible
functional roles and tagging considerations. An addi-
tional 2 ASMT region SNPs were imputed using the
program MACH v. 1.0.16 [33]. Phased haplotypes of 60
unrelated HapMap II CEU founders were used as the
reference data (CEU_r21_nr_fwd_phased). Unfortu-
nately, rs5989681 (another ASMT promoter SNP impli-
cated in depression) was not assayed directly nor
imputed successfully. An additional 29-41 continental-
ancestry-informative marker SNPs (AIMs) were assayed
in the UCSD DSPD, Scripps and bipolar disorder DNA,
to exclude participants of non-European ancestry, and
the MrOS and SOF participants were all known to be of
European ancestry. Three AANAT SNPs, rs11077821,
rs8150, and rs12942767 were also assayed in the five
groups. Each bipolar patient had been genotyped for
NTRK2 rs1387923 using a Taqman assay.
Statistical Analysis
The associations of ASMT SNPs with either the QIDS-
SR or GDS depression scales were computed with
PLINK [34], using linear regression in an additive
model, controlling for age, gender (when applicable),
and clinic site (when applicable). To control for ancestry
background, we performed a multidimensional scaling
analysis (MDS) with the AIMs and used two ancestry-
informative marker dimensions as covariates in the asso-
ciation analyses. Because we were seeking to replicate
the previous reports of Galecki et al. [12] and Soria et
al. [17] of SNPs associated with depression, a signifi-
cance criterion of P = 0.05 was chosen for ASMT
rs4446909 and AANAT rs8150. R
2 represented the per-
centage of depression variance predicted by the SNP,
excluding covariates from the model. For rs4446909, a
recessive model was also considered, but it did not
improve the evidence for association of the SNP with
depression. Association of ASMT and AANAT SNPs
with BALM was examined in the UCSD and Sleep Cen-
ter participants with a dominant model, using similar
linear regressions controlled for age, gender, and MDS
factors, and correcting for multiple testing of 610 SNPs.
The dominant model was selected because of evidence
that morningness-eveningness is inherited as a dominant
trait [35]. Among the bipolar patients, the associations
of ASMT rs4446909 and NTRK2 rs1387923 with lithium
response and Alda scale response were assessed with
SPSS, using the general linear model and backwards
stepwise logistic regression, controlling for age and
gender.
Results
Results of the regression analyses are summarized in
Table 2. As predicted, rs4446909 was significantly
associated with depressive symptoms (QIDS-SR) in the
UCSD DSPD cases and controls (P < 0.01, R
2 = 0.007).
The association of rs4446909 with depressive symptoms
in the Sleep Center patients was not significant (P =
0.10, R
2 = 0.004). Likewise, in the MrOS participants,
the association of rs4446909 with the GDS was not sig-
nificant (P = 0.06, R
2 = 0.0003), nor was it significant
among SOF participants (P = 0.26, R
2 = 0.0006).
Exploration of ASMT haplotypes using sliding windows
of 2, 3, or 4 SNPs [34] did not reveal additional signifi-
cant associations.
Only 3 SNPs in AANAT were assayed, rs8150,
rs11077821, and rs12942767. None of these were signifi-
cantly associated with the QIDS-SR or log10[GDS] in
any of the four research groups rated for depression.
The same analyses could not be done for the bipolar
disorder patients, for whom depression scales were not
collected. However, it was of interest that the rs4446909
minor allele frequency of 0.24 - 0.27 was similar in the
UCSD DSPD, Sleep Center, MrOS, SOF, and bipolar
DNAs, suggesting no association of the rs4446909 allele
with bipolar disorder. In the analysis of bipolar patients,
neither the categorical lithium response nor the Alda
score were significantly associated with either rs4446909
or rs1387923, controlling for age and gender, nor were
any significant interactions observed.
In regard to the BALM morningness-eveningness
scale, no ASMT SNP was significantly associated in the
UCSD DSPD or Sleep Center participants, controlling
for age and gender. BALM scores were not available for
the MrOS and SOF participants. Among the bipolar
patients, the BALM was nominally significantly asso-
ciated with rs4446909, controlling for rs1387923, age
and gender in ANOVA models (P = 0.009), but there
were no significant interactions. The minor A allele was
associated with a higher BALM score, indicating
Table 2 Association of ASMT rs4446909 with depression
scales.
Study rs4446909 P rs4446909 R
2 rs4446909 Beta
DSPD 0.01 0.007 -0.74
Sleep Clinic 0.10 0.004 0.40
MrOS 0.06 0.0003 0.02*
SOF 0.26 .0006 0.01*
P: nominal values, corrected for genomic inflation, are for additive association
of the minor allele of rs4446909 with the QIDS or GDS depression self-rating.
Recessive models were not more significant.
R
2: squared correlation representing percent variance explained by the
association of the depression score and rs4446909, uncorrected for covariates.
Beta: for DSPD, a negative beta indicated that as the A allele decreases in
amount (frequency), and G alleles increase, QIDS depression scores increase.
The not-significant Beta’s for the Sleep Clinic, MrOS, and SOF participants
were in the opposite direction from the DSPD sample.
* Beta for the log transform of GDS+1 suggested a 2% increase in GDS score
over the range of 1 to 16 per A allele.
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significant when correcting for the multiple testing of
610 SNPs, which had been done for testing association
with the BALM. Combining the DSPS and Sleep Clinic
samples, which was justified by the distribution of the
BALM in the samples, AANAT rs11077821 was nomin-
ally associated with the BALM (A allele associated with
greater BALM, i.e., greater morningness) with P = 0.019,
aPv a l u ew h i c hd i dn o ts u r v i v eB o n f e r r o n ic o r r e c t i o n
for multiple testing. No significant interaction of
AANAT rs11077821 with ASMT rs4446909 was
observed affecting the BALM or QIDS-SR in the com-
bined DSPS and Sleep Clinic samples, nor were any
ASMT or AANAT SNPs associated with lithium
response in the bipolar sample, nor were interaction
effects between such SNPs observed.
Discussion
These studies yielded both significant and non-signifi-
cant results, some of which suggest inability to replicate
previously-reported findings. To summarize, we were
able to replicate an association of the ASMT rs4446909
G allele with depressive symptoms in one of the four
groups examined (P < 0.01, a P value which survives
Bonferroni correction for four groups tested). In the
DSPD study participants, a negative regression indicated
that as the rare A allele decreased in frequency and the
common G allele increased, depressive symptoms mea-
sured by the QIDS-SR score tended to increase, consis-
tent with the association previously reported by Galecki
et al. [12]. In the Sleep Center, MrOS, and SOF partici-
pants, rs4446909 was not associated with depression
symptoms at the P < 0.05 level. Neither was rs4446909
associated with lithium response among bipolar partici-
pants. The R
2 values were not large in any of the
groups, suggesting that ASMT would not appear to be
an important factor in the expression of depressive
symptoms or the stability of lithium-treated bipolar dis-
order. Possibly a stronger influence of ASMT poly-
morphisms might be demonstrated in younger
populations, using different phenotyping methods. We
could not replicate an association of AANAT rs8150
with depression in any of the 4 groups, though we have
not assayed the other two SNPs necessary to examine
the strongly-associated haplotype reported by Soria et al.
[17]. Also, we have not assayed rs11077820, the one
imputed SNP in the Spanish subjects which was repli-
cated in another study, though we had assayed
rs11077821, a nearby SNP only 911 nucleotides 3’ which
was significantly associated with depression in the
WTCCC study [17] but not in our studies. We did
observe nominally significant associations of ASMT
rs4446909 and AANAT rs11077821 with the BALM
morningness-eveningness scale, implying an influence of
these SNPs upon circadian phase, but since we tested a
large number of SNPs for these associations which were
not predicted prospectively, they did not meet Bonfer-
roni significance criteria correcting for multiple testing.
A limitation of our methods was the use of self-report
depression scales which reflected the recent mood state
of the subject, rather than any specific lifetime diagnosis,
whereas the Polish and Spanish depression cases were
all diagnosed with major depressive disorders by
accepted criteria. The methods of Galecki et al. [12] and
Soria et al. [17] may have better distinguished lifetime
genetic susceptibility to depressive disorders from evi-
dence of no susceptibility, since some of our research
participants with high depressive symptom scores may
not have suffered recurrent depression, whereas some
patients with low scores at the time of testing may have
suffered episodes of depression in the past. Also, many
of the Sleep Center patients and all of the MrOS and
SOF participants were quite elderly, and it is known
that genetic susceptibility to depression may be less
influential when cerebrovascular disease and various
forms of dementia begin to alter the depressive pheno-
types [36,37].
Direct clinical evidence for low melatonin as a cause
of depression has been quite inconsistent. Our group
has not found evidence associating low melatonin with
major depression [4], but rather our evidence favored a
delayed offset of the nocturnal melatonin peak, extend-
ing after awakening [3], which might be consistent with
the recent report indicating that delayed melatonin off-
set inhibits photoperiodic responses [8]. Indeed, in our
previous data, there was some trend associating high
melatonin release with depression [4]. Similar findings
of delayed melatonin offset in depression have been
reported by others [6,38]. If the G allele of ASMT
rs4446909 tends to reduce ASMT expression and activ-
ity, that might increase the half-life of N-acetylserotonin
and thereby delay the synthesis and subsequent metabo-
lism of melatonin, thus delaying both the onset and off-
set of the nocturnal melatonin peak and delaying the
melatonin phase. The G allele was likewise associated
with delayed circadian phase as measured by the BALM
(not significant after correction for multiple testing). A
reduction of ASMT activity might have an impact on
the timing of melatonin synthesis independent of its
overall 24-hour production. Factors influencing the
sequestration of AANAT might likewise influence mela-
tonin timing.
Another possibility, perhaps implied by increased sero-
tonin associated with autism spectrum disorder and pre-
sumably with the rs4446909 G allele [13], is that a
crucial effect of reduced ASMT expression is accumula-
tion of N-acetylserotonin, which we now appreciate may
influence the BDNF-TRKB interaction [18]. It is possible
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concentrations of N-acetylserotonin. We could not
demonstrate a clinical effect in the bipolar patients uti-
lizing only 80 patients, but larger groups were needed
for the previous studies to demonstrate an effect of the
rs1387923 SNP in NTRK2. Further exploration of ASMT
and AANAT SNPs in larger pharmacogenetic studies of
NTRK2 and lithium should be encouraged. Although
psychiatry has focused primarily on serotonin and mela-
tonin, it has been known for decades that N-acetylsero-
tonin might play an independent role [39].
We have focused on the last two enzymes in melato-
nin synthesis, but numerous other genes influence the
transcription and sequestration of these enzymes, as
well as melatonin metabolism [19,40]. Among these,
MAOA, COMT, TPH1, and TPH2 have been reported to
be associated with depression, but a recent genome-
wide association study found no significant genome-
wide association, and the best candidates did not involve
these pathways [41]. MAOA is of particular interest,
both because there are several positive reports of asso-
ciation, and because MAOA may participate in regulat-
ing both in synthesis and degradation of melatonin
[42,43].
Conclusions
To summarize, our data from five research samples do
not demonstrate any strong association of AANAT and
ASMT SNPs with depression, though a weak association
with rs4446909 was replicated. We regard the overall
evidence of our group and others as sufficiently promis-
ing to invite additional more detailed studies, especially
when full sequencing of these genes in clinical samples
becomes practical. Additional understanding of melato-
nin synthesis pathways may demonstrate a more impor-
tant contribution to depression.
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